Synopsis:
This session will explore the latest pathobiological and clinical insights into psoriatic arthritis (PsA) and axial spondylarthritis (axSpA). Join us, as our esteemed panel of experts will explain the evolving role of dual interleukin (IL)-17A and IL-17F inhibition, examine the latest clinical data, and highlight strategies to inform therapeutic decision-making and disease management in spondyloarthritis (SpA).
Don’t miss this opportunity to connect with peers and stay at the forefront of therapeutic innovation in rheumatology!
This session is sponsored and organised by UCB and is intended for healthcare professionals only. UCB products will be discussed. GL-BK-2500049 Date of preparation: June 2025
Agenda:
|
|
Chairperson/s:
Prof Peter Nash, Prof Hideto Kameda
|
|
11:10 |
Welcome Remarks: Introduction Prof Peter Nash |
|
11:15 |
Pathologic significance of IL-17A&F in the spondyloarthritis disease spectrum
Prof Arthur Kavanaugh |
|
11:45 |
Unravelling the potential of IL-17A&F inhibitors from clinical results
Prof Masato Okada |
|
12:05 |
Q&A and Discussion
|
